JPWO2023008337A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2023008337A5
JPWO2023008337A5 JP2023538494A JP2023538494A JPWO2023008337A5 JP WO2023008337 A5 JPWO2023008337 A5 JP WO2023008337A5 JP 2023538494 A JP2023538494 A JP 2023538494A JP 2023538494 A JP2023538494 A JP 2023538494A JP WO2023008337 A5 JPWO2023008337 A5 JP WO2023008337A5
Authority
JP
Japan
Prior art keywords
polypeptide
sequence
seq
amino acid
sequence number
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023538494A
Other languages
English (en)
Japanese (ja)
Other versions
JP7851625B2 (ja
JPWO2023008337A1 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2022/028503 external-priority patent/WO2023008337A1/ja
Publication of JPWO2023008337A1 publication Critical patent/JPWO2023008337A1/ja
Publication of JPWO2023008337A5 publication Critical patent/JPWO2023008337A5/ja
Application granted granted Critical
Publication of JP7851625B2 publication Critical patent/JP7851625B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023538494A 2021-07-26 2022-07-22 宿主因子ｌｉｐｇをターゲットとした抗ｂ型肝炎ウイルス剤 Active JP7851625B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021121446 2021-07-26
JP2021121446 2021-07-26
PCT/JP2022/028503 WO2023008337A1 (ja) 2021-07-26 2022-07-22 宿主因子ｌｉｐｇをターゲットとした抗ｂ型肝炎ウイルス剤

Publications (3)

Publication Number Publication Date
JPWO2023008337A1 JPWO2023008337A1 (https=) 2023-02-02
JPWO2023008337A5 true JPWO2023008337A5 (https=) 2024-10-22
JP7851625B2 JP7851625B2 (ja) 2026-04-27

Family

ID=

Similar Documents

Publication Publication Date Title
AU2007276294B2 (en) Anti-NKG2A antibodies and uses thereof
EP3820499A1 (en) Tissue-specific wnt signal enhancing molecules and uses
US10654915B2 (en) Antibodies useful in passive influenza immunization
KR20100110864A (ko) 인간화된 항-인간 ｎｋｇ2ａ 모노클로날 항체
JP4287280B2 (ja) ＨＣＶＥ２グリコプロテインに対して向けられ、ｉｎｖｉｔｒｏ中和活性を有するヒトモノクローナル抗体Ｆａｂ断片
TW200407161A (en) Human monoclonal antibodies to influenza M2 protein and method of making and using same
JPH06501938A (ja) ペプチドよりなるｈｉｖ複製阻害剤
CN115043938A (zh) SARS-CoV-2及其突变株的抗体及应用
CA3193261A1 (en) Chimeric conjugates for degradation of viral and host proteins and methods of use
JPWO2020059847A5 (https=)
KR20230141853A (ko) 사베코바이러스 결합제
KR20060041163A (ko) 코로나바이러스에 의한 감염을 치료, 조절 및 예방하기위한 항바이러스 제제들
CN115667282A (zh) 针对冠状病毒的多抗原肽及含有其的免疫激活组合物
RU2011103168A (ru) Функционализированные полипептиды
Ward et al. Completion of the amino acid sequence of a Hong Kong influenza hemagglutinin heavy chain: sequence of cyanogen bromide fragment CN1
JPWO2023008337A5 (https=)
JP2019038772A5 (https=)
CN1545551B (zh) 针对丙型肝炎病毒e2糖蛋白的人单克隆抗体
US20230073821A1 (en) Antigen-binding proteins targeting coronavirus (cov) variants
AU2020280543B2 (en) Anti-hepatitis B virus antibodies and use thereof
JP2005509160A5 (https=)
WO2004087762A1 (ja) ペプチドトランスポーターの輸送活性を阻害する抗体
RU2814471C2 (ru) Новые антитела против вируса гепатита b и их применение
US20220289827A1 (en) Neutralizing antibodies to sars-cov-2 and its variants
WO2007057617A1 (fr) Proteine chimere lectine-defensine